At a glance
ClinicalIndex Comparison Record- ✓Pathologically confirmed non-small cell lung cancer
- ✓Stage IIIB, IV, or recurrent disease
- ✓Measurable or evaluable indicator lesions
- ✓History of smoking ≥100 cigarettes in lifetime
- ✕No prior chemotherapy for advanced NSCLC
- ✕No prior EGFR/HER-directed agents (gefitinib, cetuximab, trastuzumab)
- ✕No gastrointestinal tract disease or inability to take oral medication
- ✕No prior malignancy within 2 years except nonmelanoma skin cancer or cervical carcinoma in situ
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial Comparing Two Doses of Pulsed Erlotinib Prechemotherapy (PEP-C) in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Carboplatin, erlotinib hydrochloride, and 1 other intervention for Lung Cancer. Completed, enrolled 86 participants across 2 sites.
Detailed Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with paclitaxel and carboplatin may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different doses of erlotinib when given together with paclitaxel and carboplatin to compare how well they work in treating patients with stage III, stage IV, or recurrent non-small cell lung cancer.
Study Details
Timeline
Interventions
150mg
200mg/m2
1500mg